U.S. Markets closed

Sartorius Aktiengesellschaft (0NIQ.L)

LSE - LSE Delayed Price. Currency in EUR
309.51-4.00 (-1.28%)
At close: 05:56PM GMT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close313.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. VolumeN/A
Market Cap22.081B
Beta (5Y Monthly)0.64
PE Ratio (TTM)80.71
EPS (TTM)3.84
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Sartorius with clear double-digit growth in fiscal 2022

    Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability. Both divisions contributed to this development and, according to preliminary figures, recorded double-digit percentage growth in sales revenue and earnings year-over-year. For fiscal 2023, the company projects further growth and continued high profitability.

  • PR Newswire

    Sartorius with continued growth in a challenging environment

    The life science group Sartorius closed the first nine months of 2022 in both divisions with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year.

  • PR Newswire

    Sartorius to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions

    The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral thera